Payment overview · 2025
General Payments
$310.63
16 reported records · 12 companies
Healthcare provider profile · identity verified
Dan E Calleja, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MT STERLING, KY · NPI 1871532366
Verified facts
What the public records show
CMS Open Payments records show Dan E Calleja, M.D. received $310.63 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.86 | 18.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.62 | 13.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.35 | 10.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.84 | 9.3% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $28.31 | 9.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.78 | 7.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.35 | 5.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.04 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.60 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.49 | 5.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.37 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.02 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $310.63 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 91 |
| Lisinopril | Lisinopril | 345 | 93 |
| Gabapentin | Gabapentin | 265 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 60 |
| Omeprazole | Omeprazole | 230 | 64 |
| Losartan Potassium | Losartan Potassium | 226 | 63 |
| Tramadol Hcl | Tramadol Hcl | 211 | 40 |
| Metformin Hcl | Metformin Hcl | 198 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 53 |
| Alprazolam | Alprazolam | 172 | 32 |
| Eliquis | Apixaban | 151 | 20 |
| Furosemide | Furosemide | 139 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 40 |
| Potassium Chloride | Potassium Chloride | 123 | 30 |
| Montelukast Sodium | Montelukast Sodium | 109 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 37 |
| Glipizide Er | Glipizide | 105 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 33 |
| Cefuroxime | Cefuroxime Axetil | 100 | 77 |
| Simvastatin | Simvastatin | 100 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 17 |
| Carvedilol | Carvedilol | 81 | 20 |
| Sertraline Hcl | Sertraline Hcl | 79 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 23 |
| Buspirone Hcl | Buspirone Hcl | 76 | 21 |
| Prednisone | Prednisone | 70 | 46 |
| Allopurinol | Allopurinol | 69 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 20 |
| Meloxicam | Meloxicam | 67 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 21 |
| Temazepam | Temazepam | 65 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Mirtazapine | Mirtazapine | 63 | 14 |
| Levofloxacin | Levofloxacin | 58 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 11 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Bumetanide | Bumetanide | 53 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Ozempic | Semaglutide | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 21 |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Januvia | Sitagliptin Phosphate | 43 | 12 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Nystatin | Nystatin | 41 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 18 |
| Finasteride | Finasteride | 37 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 18 |
| Fluconazole | Fluconazole | 35 | 19 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Famotidine | Famotidine | 27 | 11 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $310.63 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, Ozempic, REXULTI, Rybelsus, VOQUEZNA, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error